Neurocrine price target raised to $143 from $137 at BofA

BofA raised the firm’s price target on Neurocrine to $143 from $137 and keeps a Buy rating on the shares. The firm notes Neurocrine announced positive results from the Phase 3 CAHtalyst study evaluating crinecerfont in pediatric congenital adrenal hyperplasia patients. The study met its primary showing a meaningful reduction in serum androstenedione from baseline. Furthermore, crinecerfont treatment was statistically significant on achieving a reduction from baseline glucocorticoid dose while maintaining androgen control as compared to pbo.